LAT Latigo Biotherapeutics Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
22:00
Aug 07
Aug 07
Latigo Biotherapeutics shares rose 17 percent after the clinical-stage drug developer raised.
Latigo Biotherapeutics shares rose 17 percent after the clinical-stage drug developer raised 345.6 million dollars in an upsized IPO priced at the top of its marketed range.
About LAT Analyst Coverage
Buzzberg tracks LAT (Latigo Biotherapeutics) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Bloomberg.